Hepatotoxicity associated with antifungal therapy after bone marrow transplantation: Editorial commentary

Clinical Infectious Diseases

Volumn 41, Issue 3, 2005, Pages 308-310

  Wingard, John R ^a   Leather, Helen ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; BILIRUBIN; FLUCONAZOLE;

ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BONE MARROW TRANSPLANTATION; HUMAN; LIVER INJURY; LIVER TOXICITY; NOTE; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; BONE MARROW TRANSPLANTATION; DEOXYCHOLIC ACID; DRUG COMBINATIONS; FLUCONAZOLE; HEPATITIS, TOXIC; HUMANS; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; RISK FACTORS;

EID: 22544474431     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/431595     Document Type: Note

References (15)

1. Fisher MA, Winkelmayer WC, Rubin RH, Avorn J. The hepatotoxicity of antifungal medications in bone marrow transplant recipients. Clin Infect Dis 2005; 41:301-7 (in this issue).
2. Proffitt R, Satorius A, Chiang SM, Sullivan L, Adler-Moor JP. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother 1991; 28(Suppl B):49-61.
3. Girios SB, Chaupuis F, Decullier E, Revol BG. Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Eur J Clin Microbiol Infect Dis 2005; 24:119-30.
4. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346:225-34.
5. Leenders AC, Daenen S, Jansen RL, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998; 103:205-12.
6. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340:764-71.
7. Leenders AC, Reiss P, Portegies P, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997; 11:1463-71.
8. Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98:711-8.
9. Bowden R, Chanfrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35:359-66.
10. Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000; 31:1155-63.
11. Fleming RV, Kantarjian HM, Husni R, et al. Comparison of amphotericin B lipid complex (ABLC) vs. Ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma 2001; 40:511-20.
12. Van Burik JH, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39:1407-16.
13. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351:1391-402.
14. Marr KA, Hachem R, Papanicolaou G, et al. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporine A. Transpl Infect Dis 2004; 6:110-6.
15. Trenschel R, Ditschkowski M, Elmaagacli AH, et al. Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplantation. Bone Marrow Transplant 2005; 35:583-6.